FDA Advisory panel today voted against lorcaserin, the new weight loss drug from Arena Pharmaceuticals, Inc (NASDAQ: ARNA) which is currently under FDA review with a PDUFA date of October 22, 2010.

The question for which the panel voted:

Has the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals to allow marketing approval?

Yes Votes:  5
No Votes: 9